Rejected from Cancer Research? The 7 Best Journals to Submit Next

Source: Clarivate JCR 2024, AACR and journal author guidelines, and publisher journal pages (accessed June 2026). The metric values are list figures and the editorial fit reasons are our own assessment.

1. Cancer Research Communications. This is the AACR's open-access journal covering the full spectrum of cancer science, and it is the natural landing spot for technically sound work that did not clear the flagship's first screen. It is the most common transfer destination from Cancer Research: same editorial family, same rigor expectations, a lower priority bar.

It carries a single flat article publication charge, recently held at an introductory rate near $2,550 with AACR member and waiver discounts available, so factor that cost in. The topical fit is essentially identical, which removes the scope-mismatch risk that sinks cross-journal moves.

2. Molecular Cancer Research. The AACR sister title built for molecular and cellular cancer biology with the mechanism as the contribution. It sits one tier below the flagship and is the cleanest step down when reviewers liked the biology but wanted a broader advance than the work delivered. You keep the AACR editorial culture you already formatted for.

3. Oncogene. The right home when the core advance is oncogene mechanism, signaling, or tumor-suppression biology with deep molecular detail and no clinical data. Reach for it when reviewers wanted more mechanism, not more breadth, and the signaling story is the real protagonist.

4. Cancer Letters. Strong when the molecular and translational biology of cancer, including metastasis and experimental therapeutics, is the center of gravity. It rewards mechanistic depth and moves relatively quickly, which suits work that is biology-first and time-sensitive. As an Elsevier title, it sits outside the AACR transfer system, so you submit manually.

5. Clinical Cancer Research. The AACR sibling for work with a genuine bridge from mechanism to the clinic: patient samples, biomarker validation, or an early-phase trial correlate. Pick it only if your contribution is actually the clinical consequence. A pure preclinical mechanism study does not become a Clinical Cancer Research paper by adding a clinical sentence.

6. Molecular Cancer Therapeutics. The AACR sister for therapy-focused preclinical work: drug discovery, mechanism of sensitivity and resistance, target validation in models. It fits when the contribution is a candidate therapy or a resistance mechanism rather than a basic mechanistic insight, and it carries the same AACR culture.

7. British Journal of Cancer. A broad, well-cited general cancer journal that publishes discovery, translational, and clinical work across all tumor types. Its scope is wide enough to absorb a Cancer Research near-miss when the work is genuinely cancer-first but did not clear the flagship's priority bar.

The AACR runs the Manuscript Transfer Service, and a Cancer Research decision letter declining a Research Article includes a transfer link. From there you can move your manuscript files, the peer review comments, and the reviewer identities to a second AACR journal of your choice, and you can upload a rebuttal letter that tells the recipient editors how you would address the reviewers' concerns before any re-review.

The transfer page ranks the available AACR titles by subject match plus journal metrics, and shows each title's handling times, out-to-review rate, and acceptance rate. A transfer is a routing suggestion, not an endorsement: every transferred manuscript gets a fresh editorial assessment, and the AACR cannot guarantee review or publication at the recipient journal.

Two mechanical details matter. First, only Research Articles are eligible for transfer, so a declined letter or commentary does not carry a transfer link. Second, Cancer Research Communications accepts transfers through an edit-and-resubmit pathway, so plan to revise against the reviewer comments rather than expecting an as-is move.

If you instead submit manually to a non-AACR title, you re-enter that journal's own portal and reformat to its limits: Cancer Research itself runs on ScholarOne Manuscripts (mc.manuscriptcentral.com/aacrjournals) and caps a Research Article at 5,000 words of body text with a 250-word abstract, and most peer titles set their own caps, so check before you paste.

Practical ladder by rejection reason:

• Desk-rejected for scope or weak cancer-first framing? Do not transfer to another AACR title unchanged. The scope problem follows the paper. Move to the journal whose scope actually matches the work: Molecular Cancer Research for mechanism, Oncogene for signaling, Clinical Cancer Research for a real clinical anchor, or an Elsevier title like Cancer Letters submitted manually.

• Rejected for incremental novelty but rigorous science? This is the classic transfer or step-down case.

Cancer Research Communications or Molecular Cancer Research is the next tier. Accept a transfer suggestion here if the recommended journal fits, and use the rebuttal-letter upload to pre-empt the priority concern.

• Rejected after review for thin mechanism, missing in vivo data, or weak orthogonal validation? Fix it before resubmitting anywhere. Every serious cancer-biology venue will raise the same point. Carry the revised experiments and a rebuttal letter into the transfer or the manual resubmission.

In our pre-submission review work with Cancer Research manuscripts, the rejections we see most often cluster into four named patterns. Each is journal-specific and testable against your own manuscript, which is what makes them worth checking before you resubmit anywhere.

The mechanism that stops at correlation. Across our Cancer Research pre-submission reviews, the single most common reviewer trigger is a central claim supported by association rather than causation. A manuscript shows that a gene is overexpressed in tumors and that knockdown changes a phenotype, but never establishes the mechanistic chain or rules out alternative explanations with an orthogonal experiment.

Cancer Research wants the mechanism to be the contribution, so reviewers expect a rescue experiment, a structure-function manipulation, or a second independent line of evidence that nails the causal step. Add the causal experiment, and a borderline paper often clears review. Without it, a strong correlative story reads as preliminary.

This is testable: look at your central figure and ask whether a skeptical reviewer could reconstruct the causal claim from the data, or only an association.

Lab-model results presented without in vivo or orthogonal validation. A second recurring pattern in the Cancer Research manuscripts we review is a finding established entirely in one cell line or one assay, framed in the abstract as a generalizable cancer mechanism, with no in vivo confirmation and no second model. The editorial question at this journal is not "does it hold in this line?"

but "does it hold across the system the way a broad cancer advance should?" Reviewers consistently flag the gap between the breadth of the claim and the narrowness of the supporting models. The fix is a confirmatory in vivo experiment or a second orthogonal system, or an honest reframing of the contribution as a mechanistic finding in a defined context rather than a general one.

Descriptive or pathway-local work wearing a mechanism label. We see manuscripts where the real output is a description, a profiling dataset, a single-pathway observation, or a confirmatory result, presented with mechanistic language the data do not support. Cancer Research editors screen early for studies that are descriptive at their core, because a descriptive advance, however clean, is rarely a fit for the flagship.

Check that your central result is a mechanistic or conceptual advance the field can build on, not a careful description of a system that was already understood. If it is descriptive, Molecular Cancer Research or an Elsevier title is usually the better target, not a resubmission of the same framing.

Scope drift into general biology, methods, or clinic-thin translation. The fourth pattern is a paper whose true center of gravity is general cell biology, a new method, or a clinical or epidemiology question, with a cancer wrapper added for fit. The journal wants cancer biology to be the protagonist, not a use case.

When the manuscript is really a methods paper, a basic-biology study with a tumor example, or a clinical correlation with a thin mechanistic backbone, the desk filter removes it fast regardless of quality. Read your own abstract and ask: is a generalizable cancer mechanism the actual subject, or a wrapper around a different field's question? If it is a wrapper, the right move is a different journal, not a resubmission.

Don't just resubmit the same file down the ladder. The fastest way to collect a second rejection is to send an unrevised manuscript to a journal that screens for the same thing Cancer Research did, and some manuscripts need real work, not a faster next submission. A desk rejection for scope is a routing problem you can fix by choosing the right journal and reframing the contribution.

A post-review rejection for thin mechanism, missing in vivo data, or weak orthogonal validation is a substance problem, and the same concerns will reappear at any serious cancer-biology venue. Be honest about which one you got.

Two cases call for real work before resubmitting, not a faster next submission. First, if reviewers questioned whether the mechanism was causal, the manuscript needs the rescue experiment, the structure-function manipulation, or the second independent line of evidence it was missing. Second, if breadth or generalizability was challenged, an in vivo experiment or a second model is usually the only fix.

Appealing is rarely worth it: a scope or novelty rejection is an editorial judgment, not a factual error, and the appeal queue is slower than a clean resubmission or transfer to a better-fit journal.